USD 14.29 Billion
Report ID:
SQMIG35J2106 |
Region:
Global |
Published Date: June, 2024
Pages:
219
|Tables:
101
|Figures:
66
Bleeding Disorders Treatment Market size was valued at USD 15.48 Billion in 2023 and is poised to grow from USD 16.76 Billion in 2024 to USD 31.72 Billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).
The global bleeding disorders treatment market is characterised through a strong trajectory driven by using several key factors. The growing incidence of bleeding problems, including hemophilia and von Willebrand disorder, serves as a primary driver, necessitating advanced therapeutic interventions. Technological improvements in hemostasis control, such as the development of recombinant clotting elements and gene treatment options, similarly propel market boom.
However, demanding situations include the excessive value of advanced remedies and constrained get entry to in sure areas. Geographically, North America and Europe lead the market because of mounted healthcare infrastructure. Key trends involve the adoption of prophylactic treatments and ongoing studies in gene remedy, shaping the panorama of bleeding problems treatment globally.
Global Market Size
USD 14.29 Billion
Largest Segment
Hemophilia A
Fastest Growth
Von Willebrand Disease
Growth Rate
8.3% CAGR
To get more reports on the above market click here to Buy The Report
The global Bleeding Disorders Treatment market is segmented into disorder type, treatment type, drug class and region. Based on disorder type, it is divided into Hemophilia A, Hemophilia B, Von Willebrand Disease, Others. Based on treatment type, the market is segmented into Recombinant clotting factors, plasma-derived clotting factors, desmopressin, antifibrinolytics, gene therapy. Based on drug class, the market is segmented into Plasma Derived Coagulation Factor (Factor VIII, Factor IX, Factor for Von Willebrand Disease, Activated Prothrombin Complex Concentrate), Recumbent Coagulation Factor (Factor VIII, Factor for Von Willebrand Disease, Factor IX), Desmopressin, Antifibrinolytics, Fibrin Sealants, Others. Based on region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.
Analysis by Disorder Type
Hemophilia A is greater well-known in comparison to other bleeding problems. It is characterised by way of a deficiency of clotting element VIII, and advancements in recombinant clotting component remedies have drastically progressed patient results. Hemophilia A often receives extra recognition in phrases of studies, development, and remedy options because of its better incidence.
VWD, even though much less not unusual than hemophilia, has been gaining attention with advancements in diagnostic capabilities, main to advanced detection and prognosis. Growing awareness of VWD and ongoing research inside the discipline make a contribution to an elevated analysis charge. Innovations in remedy alternatives for VWD, such as recombinant von Willebrand aspect cures, might also force its increase.
Analysis by Drug Class
The bleeding disorders treatment market is segmented by drug classes, including plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, and others. Plasma-derived and recombinant coagulation factor concentrates are the most prominent segments, owing to their efficacy in treating hemophilia A and B. The rise in prophylactic treatments and advancements in recombinant technologies are driving the demand in these segments. Desmopressin is widely used for mild hemophilia and von Willebrand disease, offering a non-blood product alternative that reduces infection risks associated with plasma-derived products.
Antifibrinolytics, such as tranexamic acid, play a crucial role in managing bleeding episodes in various disorders, providing an adjunctive treatment to factor concentrates. The "others" category includes emerging therapies like gene therapy and monoclonal antibodies, which are showing promise in clinical trials and could revolutionize the market landscape. The increasing prevalence of bleeding disorders, coupled with ongoing research and development, is expected to drive growth across all drug class segments, enhancing patient outcomes and expanding market opportunities.
To get detailed analysis on other segments, Request For Free Sample Report
North America, especially the USA, is expected to dominate the bleeding disorders treatment market. The place has a properly-established healthcare infrastructure, higher incidence of bleeding issues, and vast cognizance approximately superior treatment options. Access to novel treatment plans and a excessive stage of studies and development activities make contributions to North America's dominance.
The Asia-Pacific area is expected to be the fastest-growing market for bleeding issues treatment. Factors together with a huge and growing old population, increasing healthcare spending, and improving healthcare infrastructure make contributions to the growth. Rising cognizance, improvements in diagnostics, and a growing attention on uncommon illnesses are probable to power demand for bleeding disorders treatments on this region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Increasing Prevalence Of Bleeding Disorders
The growing incidence of bleeding disorders, consisting of hemophilia and von Willebrand sickness, creates a growing demand for advanced treatment modalities. Technological improvements in hemostasis management, which includes recombinant clotting factors and gene treatment plans, make a contribution to greater powerful and targeted interventions.
Restraints
High Cost Associated With Advanced Treatment Modalities
One of the principle marketplace restraints is the high fee related to superior remedy modalities poses a big barrier, restricting get entry to to those remedies in certain areas and for economically challenged patients. Regulatory complexities and the prolonged approval strategies for brand spanking new remedies additionally avert the fast advent of revolutionary solutions.
Request Free Customization of this report to help us to meet your business objectives.
The aggressive surroundings of the Bleeding Disorders Treatment marketplace is dynamic and is characterized via the presence of major pharmaceutical companies and biotechnology corporations striving to establish a sturdy marketplace foothold. Established gamers including Novo Nordisk, Shire (now part of Takeda), and Bayer dominate the marketplace with considerable portfolios of clotting issue merchandise and advancements in remedy alternatives. These enterprise leaders continually spend money on studies and improvement to introduce novel treatment plans, ensuring a aggressive aspect.
Top Player’s Company Profiles
Alnylam Pharmaceuticals Inc.
Roche Holding AG
Shire Plc. (earlier Baxalta) (Ireland)
AbbVie Inc.
Wellona Pharma
Sobi International AB
BioMarin Pharmaceutical, Inc.
UniQure NV
Pharming Group N.V.
HEMA BioSciences
Recent Developments
September 2023: ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, has received approval from the U.S. Food and Drug Administration (FDA). This marks a huge milestone for the primary-of-its-type excessive-sustained thing VIII replacement remedy.
October 2023: Sanofi SA (SASY.PA) has received approval from the U.S. Food and Drug Administration for its remedy designed to deal with hemophilia A, a hereditary bleeding disease. The French pharmaceutical business enterprise anticipates launching the remedy inside the United States in April.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
Global Bleeding Disorders Treatment market analysis famous a dynamic marketplace with a number of standout trends and problems. The marketplace is driven by means of a surge in incidence, technological advancements, and heightened focus. However, restraints include high treatment fees and regulatory complexities. Recombinant clotting factors dominate treatment alternatives, with gene remedy rising as a transformative fashion. North America leads because of superior healthcare infrastructure, even as the Asia-Pacific location suggests potential for rapid boom. Key tendencies contain personalised medicine, gene therapy research, and a shift closer to prophylactic treatments. These dynamics underscore a dynamic panorama, marked by means of innovation and a affected person-centric technique in bleeding problems remedy globally.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 14.29 Billion |
Market size value in 2031 | USD 29.29 Billion |
Growth Rate | 8.3% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Bleeding Disorders Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Bleeding Disorders Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Bleeding Disorders Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Bleeding Disorders Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2106
sales@skyquestt.com
USA +1 351-333-4748